A phase 3 trial shows a personalized mRNA vaccine cut melanoma recurrence or death risk by 42% when added to pembrolizumab.
Posts tagged as “mRNA vaccine”
A personalized mRNA vaccine combined with pembrolizumab reduced the risk of melanoma returning or death by 42% in a phase III trial.
UW Medicine says the newly approved mRNA flu vaccine, mFLUSIVA, is about 30% more effective than traditional shots for adults 50 and older.
The FDA has approved the first mRNA influenza vaccine, mFLUSIVA, which could provide better protection against the flu.